{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T05:19:59Z","timestamp":1787635199755,"version":"build-2736575974"},"reference-count":35,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T00:00:00Z","timestamp":1786233600000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["analyticalsciencejournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Luminescence"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    A simple, rapid, precise, and selective first derivative spectrofluorimetric (\n                    <jats:sup>1<\/jats:sup>\n                    D) technique was suggested for repaglinide (REP) and febuxostat (FEB) simultaneous quantitation in pure, spiked human plasma samples and dosage forms. The approach was based on the first derivative transformation of the conventional fluorescence emission spectra. Excitation was fixed at 250\u2009nm, and the first derivative of the emission spectra was recorded for each sample. Repaglinide (REP) was measured at 336.5\u2009nm and febuxostat (FEB) at 363.5\u2009nm in presence of each other using 0.2\u2010M acetate buffer pH\u20093.9. Several experimental factors were examined and adjusted based on their effect on the fluorescence intensity. The validation was performed in accordance with ICH guidelines and the amplitude first derivative (\n                    <jats:sup>1<\/jats:sup>\n                    D) versus concentrations curves covered concentration ranges of 0.01\u20130.18\u2009\u03bcg\/mL for REP and 0.03\u20130.2\u2009\u03bcg\/mL for FEB. The quantification limits (LOQs) were 0.007 and 0.026\u2009\u03bcg\/mL for (REP) and (FEB), whereas lower detection limits (LODs) were 0.002 and 0.009\u2009\u03bcg\/mL, respectively. The suggested approach was effectively used to determine the two drugs in spiked human plasma samples in ranges 0.01\u20130.2\u2009\u03bcg\/mL for REP and 0.05\u20130.2\u2009\u03bcg\/mL for FEB. The proposed technique was effectively used to identify the (REP) and (FEB) in multiple pharmaceutical products.\n                  <\/jats:p>","DOI":"10.1002\/bio.70606","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T04:34:48Z","timestamp":1786336488000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Green Sensitive Derivative Emission Spectrofluorimetry for the Estimation of Repaglinide and Febuxostat Simultaneously in Dosage Forms and Spiked Human Plasma"],"prefix":"10.1002","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-0079-1841","authenticated-orcid":false,"given":"Aya A.","family":"Marie","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Faculty of Pharmacy Horus University\u2010Egypt  New Damietta Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Roshdy","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Faculty of Pharmacy Horus University\u2010Egypt  New Damietta Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,9]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-019-01456-w"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.22270\/jddt.v9i3.2676"},{"key":"e_1_2_9_4_1","first-page":"10","article-title":"Development, Validation and Stability Study of UV Spectrophotometric Method for Determination of Repaglinide in Bulk and Pharmaceutical Dosage Forms","volume":"1","author":"Mishra J.","year":"2016","journal-title":"Journal of Innovative Applied Pharmaceutical Sciences"},{"key":"e_1_2_9_5_1","first-page":"69","article-title":"UV\u2010Visible Spectrophotometry of Repaglinide in Bulk and in Formulation by Using Methyl Orange as Reagents","volume":"2","author":"Sharma S.","year":"2011","journal-title":"Journal of Iranian Chemical Research"},{"key":"e_1_2_9_6_1","first-page":"985","article-title":"Application of Simultaneous Equation Method for Determination of Metformin HCl and Repaglinide in Bulk, Combined Dosage Form, and Dissolution Samples by UV\u2010Spectrophotometer","volume":"15","author":"Bhavyasri K.","year":"2023","journal-title":"Journal of Pharmaceutical Sciences and Research"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10895-012-1099-0"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.4103\/0250-474X.65029"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules24244430"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00769-012-0942-y"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/22297928.2020.1861975"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.2116\/analsci.19.1675"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2006.12.010"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/22297928.2019.1622450"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0466-4"},{"key":"e_1_2_9_16_1","article-title":"A Simple UV Spectrophotometric Method for the Determination of Febuxostat in Bulk and Pharmaceutical Formulations","volume":"2","author":"Bagga P.","year":"2011","journal-title":"International Journal of Pharmaceutical Sciences and Research"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.13005\/ojc\/290429"},{"key":"e_1_2_9_18_1","first-page":"23","article-title":"Development and Validation of a Novel Stability Indicating UV\u2010Spectrophotometric Method for Estimation of Febuxostat in Bulk and Pharmaceutical Formulation (Tablets)","volume":"9","author":"Kaur M.","year":"2018","journal-title":"Pharmaceutical Methods"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.microc.2022.108191"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1098\/rsos.210354"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.saa.2020.119239"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1039\/C6RA11246C"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.31083\/ph.2013.2229"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.2936"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13285"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/chromsci\/bms192"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2019.121764"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio-2018-0219"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0360-7"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.3390\/biom14010099"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1586\/ecp.12.39"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.3390\/analytica5030030"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.analchem.0c01887"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2011.04.004"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/2193-1801-2-194"},{"key":"e_1_2_9_36_1","first-page":"40","article-title":"Validation of Analytical Procedures: Text and Methodology Q2(R1)","volume":"1","author":"ICH Harmonised Tripartite Guidelines","year":"2013","journal-title":"Acta Pharmaceutica Sinica B"}],"container-title":["Luminescence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bio.70606","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/bio.70606","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bio.70606","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T05:00:59Z","timestamp":1787634059000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/bio.70606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1002\/bio.70606"],"URL":"https:\/\/doi.org\/10.1002\/bio.70606","archive":["Portico"],"relation":{},"ISSN":["1522-7235","1522-7243"],"issn-type":[{"value":"1522-7235","type":"print"},{"value":"1522-7243","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"2026-06-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70606"}}